Intellia Therapeutics, Inc. (NTLA) reported an insider ownership change involving Edward J. Dulac III, who sold shares of the company’s common stock on July 22, 2026, in connection with the vesting of restricted stock units. The Form 4 discloses a sale of 8,111 shares of Intellia common stock at a reported weighted-average price of $11.25 per share. Based on that average price, the transaction represented roughly $91,249 in gross proceeds. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.28 per share, inclusive. The filing notes that the sale was a mandatory “sell-to-cover” transaction used to satisfy Dulac’s tax withholding obligations upon the vesting of RSUs on July 22, 2026. The company specifically stated that the transaction did not represent a voluntary or discretionary open-market trade by the reporting person. The filing was signed on July 24, 2026, by James Basta as attorney-in-fact for Dulac. The provided filing text does not state Dulac’s beneficial ownership after the transaction or provide additional details on the underlying RSU grant beyond the vesting-related tax withholding explanation.
Stock detail
Intellia Therapeutics (NTLA) stock price, chart, and key data
View Intellia Therapeutics stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Intellia Therapeutics
NTLA · XNAS
-$0.11 (-1.01%) past day
$10.78
After hours $10.75 (+0.70%)
Key metrics
Earnings
Quarterly results and the next expected release
FY25 Q2
Q3
Q4
FY26 Q1
Q2
Q3
Day range
$10.17 - $11.35
52-week range
$7.95 - $28.24
Close price
$10.67
Market cap
$1.5B
P/E ratio
-4.72
Beta
1.77
About the company
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.
Ticker holders
Review politician disclosures and insider transactions in tabs.
Holder directory
Select a heading to reorder by name, activity date, buy/sell, or displayed value.
#1Don Beyer
democrat · House · VA-8
- Sell$15,001 / $32,501 / $50,000
- Sell$15,001 / $32,501 / $50,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,001 / $8,001 / $15,000
#2Tom Carper
democrat · Senate · DE
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Buy$1,000 / $8,000 / $15,000
- Buy$1,000 / $8,000 / $15,000
Market action
A concise summary of the latest filing, transaction, or market-moving item.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app